Main Menu
Menu

Council for Innovation Promotion

Publish Date
BlogFact Checks
Fact Check: The Data Doesn’t Support the Existence of So-Called Patent “Thickets”

Several academic authors recently published an article in Health Affairs Forefront advising policymakers in Congress and at the USPTO on the best...

Resources
Infographics & Fact Sheets
PREVAIL in Comparison to the Current and Previous Administration’s Procedures for PTAB
News
Fake gifts flooding online marketplaces this holiday season. Here’s how to avoid getting scammed.
KTNV-TV
Blog
‘Tis the Season — of Counterfeits?

Counterfeiting is a multi-billion-dollar enterprise that puts consumers at serious risk. Poorly-made laptop batteries can overheat. Knock-off cosmetics may contain toxic chemicals....

News
The Patent Eligibility Restoration Act (PERA) Could Provide A Much Needed Boost To Key Technology Sectors Of The U.S. Economy
Mondaq
Press Releases
Council for Innovation Promotion Statement on RALIA and the BIA

WASHINGTON (November 10, 2025) — Recently, Representatives Thomas Massie (R-KY), Marcy Kaptur (D-OH), Michael Cloud (R-TX), Warren Davidson (R-OH), Paul Gosar (R-AZ),...

Blog
This Month in IP: October 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From firefighting...

Blog
C4IP Coalition Updates: October 2025

October Highlights: C4IP Advocates for the Patent Eligibility Restoration Act On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a...

News
C4IP Urges USTR to Use USMCA Joint Review to Address Shortcomings on IP Protections
IPWatchdog
Resources
Public Comments
C4IP Comments RE: India’s Invitation to Comment on Its Drug Approval Regime
Resources
Public Comments
C4IP Comments RE: Operation of the Agreement between the United States of America, the United Mexican States, and Canada (USTR-2025-0004)
Blog
Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth

The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs....

Op-Eds:

Op-Eds:

Congress Should Pass Tillis-Coons Patent Eligibility Bill,

11/18/2022
News:

News:

Is China set to pass the US as the world’s lead innovators?,

11/15/2022
Op-Eds:

Op-Eds:

Protect the value of American invention,

11/12/2022
News:

News:

How China steals U.S. intellectual property,

11/10/2022
Blog:

Blog:

On TRIPS waiver extension, America must stand up — not stand by,

11/09/2022
Op-Eds:

Op-Eds:

Biden’s cancer moonshot will miss without intellectual property,

11/09/2022
Blog:

Blog:

Don’t suspend IP protections on Covid-19 diagnostics and therapeutics,

10/31/2022
Press Releases:

Press Releases:

Bipartisan Advocacy Coalition From Former Obama and Trump Officials Launches Major Advertising Campaign,

10/26/2022
Ads:

Ads:

B4IP Like Me! Ad Series,

10/25/2022
Ads:

Ads:

B4IP Like Me! Video Ad Series,

10/23/2022
News:

News:

Iancu-Backed Group Urges Lawmakers To Support Tillis IP Bill,

10/19/2022
News:

News:

Letters Seek to Dispel Gene Patent ‘Scaremongering’ Surrounding Tillis’ Patent Eligibility Bill,

10/18/2022
Scroll to Top